Compounds · Oral incretins · continued

Orforglipron as a non-peptide: what changes when the molecule is small posts 31–31

Compounds › Oral incretins orforglipron SOUL trial PIONEER programme

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

GEldridgeTL3Regular1 Sep 2024 · edited#31

d.bakker, post #4: Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure. Go to post

Coming back to post #29, because the follow-up matters more than the original answer.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

1 like in reply to #4 23mo

This topic was referenced in

The SOUL trial and oral semaglutide cardiovascular outcomesCompounds › Oral incretins · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Dose numbers for oral formulations are not comparable to injectable ones Compounds › Oral incretins orforglipron PIONEER programme SOUL trial On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+19	23	39k	6mo
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
Why fasting instructions for oral semaglutide are not optional advice Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Solved Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…	+70	74	1.1k	23d
The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins orforglipron oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…		2	7.1k	9h
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h

Related topics — sharing the tags orforglipron, SOUL trial, PIONEER programme

Topic	Participants	Replies	Views	Activity
Why oral semaglutide needs an absorption enhancer at all — what changed since Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Solved Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it before…		2	61k	14mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins orforglipron oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…		2	7.1k	9h
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Compounds › Oral incretins oral semaglutide randomised trial PIONEER programme SOUL trial Solved Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…	+130	135	11k	7mo